C5237476_NCI_CDISC-GLOSS | Knowledge4COVID-19

Property	Value
?:definition	Medicinal products identified in the protocol as those that may be administered to subjects when the efficacy of the investigational medicinal product (IMP) is not satisfactory, the effect of the IMP is too great and is likely to cause a hazard to the patient, or to manage an emergency situation. [After EU-CTR Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014\' dd 28 June 2017]
?:hasCUIAnnotation	<https://research.tib.eu/covid-19/entity/C5237476>
?:hasGeneratedBy	<https://research.tib.eu/covid-19/SourceName/NCI_CDISC-GLOSS>
?:type	<https://research.tib.eu/covid-19/vocab/AnnotationDefinition>

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/C5237476_NCI_CDISC-GLOSS>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/C5237476_NCI_CDISC-GLOSS>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all